-
-epidemiological methods on human study populations to identify molecular mechanisms that can serve as future targets for early detection, prevention, and treatment. Our lab is at the forefront of Alzheimer’s
-
to identify molecular mechanisms that can serve as future targets for early detection, prevention, and treatment. Our lab is at the forefront of Alzheimer’s genetics research, and has a strong international
-
of theranostic radioligands targeting tumor-associated proteases. Project overview: The Radiopharmacy group has extensive expertise in the development of radiolabeled ligands for proteases implicated in human
-
research activities within the Radiopharmacy (CREANT) department and the Molecular Imaging Center Antwerp (MICA), focusing on the preclinical evaluation of theranostic radioligands targeting tumor